Gail Farfel

(Dr. Gail Farfel Ph.D.)

Currently holds positions in Zogenix Inc and DURECT Corp

Positions

Position Company Period
Executive Vice President, Chief Development Officer Zogenix Inc July 6, 2015 -
Independent Director DURECT Corp April 23, 2019 -
Chief Clinical Development and Regulatory Officer Marinus Pharmaceuticals Inc Dec. 1, 2012 - Jan. 1, 2015
Gail Farfel's trades of ProMIS Neurosciences Inc's stock


Loading...
Purchase Sale Planned purchase Planned sale Net purchase Net sale Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PS: Planned sale, O: Option / Other
Notification date Transaction date B/S Transaction type Nb. shares
Price
Value
Number of shares Price Value Details
2022-12-16 2022-12-14 B Purchase
1,000 +100.0%
4.94
USD 4,940
1,000 +100.0% 4.94 USD 4,940
2022-12-08 2022-12-06 B Purchase
1,000 +inf%
5.70
USD 5,700
1,000 +inf% 5.70 USD 5,700
2022-05-18 2022-05-18 B Purchase
29,911 +42.7%
0.41
USD 12,201
29,911 +42.7% 0.41 USD 12,201
2022-05-18 2022-05-16 B Purchase
25,300 +56.5%
0.39
USD 9,811
25,300 +56.5% 0.39 USD 9,811
2022-05-13 2022-05-13 B Purchase
9,250 +26.0%
0.40
USD 3,700
9,250 +26.0% 0.40 USD 3,700
2022-05-13 2022-05-12 B Purchase
1,500 +4.4%
0.39
USD 585
1,500 +4.4% 0.39 USD 585
2022-05-13 2022-05-11 B Purchase
9,950 +41.3%
0.40
USD 3,973
9,950 +41.3% 0.40 USD 3,973
2022-05-12 2022-05-10 B Purchase
2,339 +10.8%
0.41
USD 950
2,339 +10.8% 0.41 USD 950
2022-05-10 2022-05-10 B Purchase
4,250 +24.3%
0.40
USD 1,679
4,250 +24.3% 0.40 USD 1,679
2022-05-10 2022-05-09 B Purchase
17,500 +inf%
0.39
USD 6,906
17,500 +inf% 0.39 USD 6,906
2020-05-13 2020-05-12 PS Planned sale
2,573 -33.8%
28.21
USD 72,584
2,573 -33.8% 28.21 USD 72,584
2015-04-23 2015-04-21 PS Planned sale
30,000 -100.0%
9.48
USD 284,511
30,000 -100.0% 9.48 USD 284,511
// ... existing code ... // ... rest of the file ...